XML 22 R11.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Other Investments | 3 Months Ended
--- | ---
Mar. 31, 2024
Investments, All Other Investments [Abstract] |
Other Investments | Other Investments In prior years the Company made minority ownership strategic investments. As of March 31, 2024 and December 31, 2023, the aggregate carrying amount of the Company’s strategic investments in non-publicly traded companies was $19.0 million and $32.0 million, respectively. These investments are measured at initial cost, minus impairment, if any, and plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Cumulative impairments of strategic investments in equity investments without readily determinable fair values still held as of March 31, 2024 and December 31, 2023 were $23.0 million and $15.0 million, respectively. As a part of the acquisition of each of the Company’s other investments, the Company determines whether an investment or other interest is considered a variable interest. As of both March 31, 2024 and December 31, 2023, the Company held an interest in one entity that was concluded to be a variable interest for which the Company was not the primary beneficiary as the Company did not have the power to direct the activities that most significantly impact the economic performance of the variable interest entity. As of March 31, 2024 and December 31, 2023, the carrying value and maximum exposure to loss of the Company’s variable interests were zero and $13.0 million, respectively, which are recorded in other investments in the Company’s Condensed Consolidated Balance Sheets. In connection with the preparation of the financial statements for the three months ended March 31, 2024 and 2023, the Company performed a qualitative assessment of potential indicators of impairment and determined that indicators existed for certain of its other investments with carrying amounts of $13.0 million and $10.0 million, respectively. During the three months ended March 31, 2024, the anticipated funding for one of its other investments was not secured within the expected timeframe. The Company considered both of the underlying companies’ operating cash flow requirements over the next year, liquid asset balances to fund those requirements and the underlying companies’ inability to raise funds as indicators of impairment. Due to these indicators, the Company assessed the valuation of these investments and determined the fair values to be negligible and the impairments to be other-than-temporary in nature. As a result, the Company recorded an impairment expense of $13.0 million for the three months ended March 31, 2024 and $10.0 million for the three months ended March 31, 2023, which consisted of the full impairment of one of our other investments in each period. The impairment expenses were recorded within impairment of other investments on the Condensed Consolidated Statements of Operations and Comprehensive Loss and as a reduction to the investment balances within other investments on the Condensed Consolidated Balance Sheets.

X
- Definition The entire disclosure for other investments. + References No definition available. + Details
Name: | lyel_OtherInvestmentsTextBlock
Namespace Prefix: | lyel_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsAllOtherInvestmentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration